Pomdoctor Limited (POM) details four-tier revenue model and 2025 growth
Rhea-AI Filing Summary
POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, outlined a four-tier diversified revenue structure designed to build on its established internet hospital, physician network and pharmaceutical supply chain while scaling technology-enabled services. The four tiers are B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical real-world study (RWS) and real-world data (RWD) services.
The company reported audited net revenues of RMB399.9 million (approximately US$59.04 million) for fiscal 2025, compared with RMB304.9 million in 2023 and RMB342.6 million in 2024, and believes this growth provides a foundation for additional AI-driven, recurring and institutional revenue streams. Management emphasized that traditional healthcare operations remain central, while AI, wearable technologies, remote patient monitoring and data capabilities are being integrated to build a predictive healthcare data and services infrastructure.
Positive
- None.
Negative
- None.
Key Figures
Net revenues FY 2025: RMB399.9 million (approximately US$59.04 million)
Net revenues FY 2023: RMB304.9 million
Net revenues FY 2024: RMB342.6 million
+1 more
4 metrics
Net revenues FY 2025
RMB399.9 million (approximately US$59.04 million)
Audited net revenues for fiscal year 2025
Net revenues FY 2023
RMB304.9 million
Audited net revenues for fiscal year 2023
Net revenues FY 2024
RMB342.6 million
Audited net revenues for fiscal year 2024
Revenue tiers
4
Four-tier diversified revenue structure combining B2C, AI, B2B and pharma data services
Key Terms
remote patient monitoring, real-world data, real-world study, pharmaceutical supply chain operations, +1 more
5 terms
remote patient monitoring medical
"Through wearable devices and remote patient monitoring (“RPM”) technologies"
Remote patient monitoring is the ongoing collection and transmission of a person’s health data (such as heart rate, blood sugar, or blood pressure) from home or another non-clinical setting to healthcare providers using connected devices and secure networks. For investors, it matters because it can reduce hospital visits, create steady service and device revenue, and change how care is paid for—think of it as a home security system for health that can lower costs and improve outcomes.
real-world data medical
"pharmaceutical real-world study (“RWS”) and real-world data (“RWD”) services"
Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.
real-world study medical
"pharmaceutical real-world study (“RWS”) and real-world data (“RWD”) services"
A real-world study collects information on how a drug, device or medical practice performs during ordinary use outside tightly controlled clinical trials, like observing how a car behaves on everyday roads rather than on a test track. Investors care because these studies can reveal whether a product works in typical patients, affect regulatory approvals, coverage and sales forecasts, and change expectations about long-term costs, demand and competitive advantage.
pharmaceutical supply chain operations technical
"patient service infrastructure and pharmaceutical supply chain operations"
chronic disease membership services medical
"developing AI-enabled chronic disease membership services that combine continuous health monitoring"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What four revenue tiers did POMDOCTOR (POM) highlight in its August 2026 update?
POMDOCTOR outlined a four-tier structure: B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services. Together they are intended to form an integrated, diversified healthcare ecosystem anchored by its internet hospital and supply chain.
How did POMDOCTOR (POM) describe its audited net revenues for fiscal 2025?
POMDOCTOR reported audited net revenues of RMB399.9 million (approximately US$59.04 million) for fiscal 2025, compared with RMB304.9 million in 2023 and RMB342.6 million in 2024. The company believes this continued growth supports further expansion of technology-enabled and recurring revenue lines.
What is POMDOCTOR’s (POM) strategy for AI-enabled chronic disease management?
POMDOCTOR is developing AI-enabled chronic disease membership services using wearable devices, remote patient monitoring and AI analytics to track indicators like heart rate and blood pressure. It aims to offer subscriptions with ongoing monitoring, health reports, risk alerts and physician support to generate recurring, higher-margin revenue.
How does POMDOCTOR (POM) plan to use real-world data (RWD) and real-world studies (RWS)?
POMDOCTOR is building a multidimensional healthcare data ecosystem to support pharmaceutical RWS and RWD services. After authorization, standardization and de-identification, data from care interactions and monitoring could help pharma and healthcare organizations with treatment analysis, adherence assessment and outcomes research.
Which pharmaceutical companies has POMDOCTOR (POM) partnered with so far?
Through its subsidiaries, POMDOCTOR has entered sales and purchase agreements with Jiangsu Hansoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical and Eddingpharm (Suzhou). These relationships support product access and supply chain coordination and may underpin future RWS/RWD service expansion.
How does POMDOCTOR (POM) position its traditional operations versus new technology services?
Management stated that its internet hospital, physician network and pharmaceutical supply chain remain essential and are not being abandoned. Instead, they provide real-world scenarios and resources as POMDOCTOR integrates AI, wearable technologies, remote patient monitoring and data capabilities into a predictive healthcare infrastructure.